|
US2373192A
(en)
|
1943-03-13 |
1945-04-10 |
Walter M Lauer |
Antioxidants
|
|
US4567253A
(en)
|
1984-02-03 |
1986-01-28 |
Tony Durst |
2-Substituted derivatives of podophyllotoxin and etoposide
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
US8178304B2
(en)
|
2000-10-06 |
2012-05-15 |
Smith Terry J |
Diagnostic methods relating to Graves' disease and other autoimmune disorders
|
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
|
BRPI0116728B1
(pt)
|
2001-01-05 |
2018-10-30 |
Pfizer Inc. |
anticorpos para receptor de fator de crescimento i semelhante à insulina
|
|
US7081454B2
(en)
|
2001-03-28 |
2006-07-25 |
Bristol-Myers Squibb Co. |
Tyrosine kinase inhibitors
|
|
AR035885A1
(es)
|
2001-05-14 |
2004-07-21 |
Novartis Ag |
Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
WO2005016970A2
(en)
|
2003-05-01 |
2005-02-24 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
WO2005058967A2
(en)
|
2003-12-16 |
2005-06-30 |
Pierre Fabre Medicament |
Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
|
|
TWI378934B
(en)
|
2004-04-02 |
2012-12-11 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2006080450A1
(ja)
|
2005-01-27 |
2006-08-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Igf-1r阻害剤
|
|
ES2385054T3
(es)
|
2005-12-13 |
2012-07-17 |
Medimmune Limited |
Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
|
|
TW200801008A
(en)
|
2005-12-29 |
2008-01-01 |
Abbott Lab |
Protein kinase inhibitors
|
|
US7612178B2
(en)
|
2006-03-28 |
2009-11-03 |
Biogen Idec Ma Inc |
Anti-IGF-1R antibodies and uses thereof
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
HRP20140688T1
(hr)
|
2006-07-07 |
2014-10-24 |
Bristol-Myers Squibb Company |
Inhibitori piroltriazin kinaze
|
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
|
PL2077830T3
(pl)
|
2006-10-17 |
2013-04-30 |
Lithera Inc |
Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
|
|
US20100216779A1
(en)
|
2007-06-01 |
2010-08-26 |
Glaxosmithkline Llc |
Imidazopyridine Kinase Inhibitors
|
|
US7981903B2
(en)
|
2007-08-08 |
2011-07-19 |
Glaxosmithkline Llc |
2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
|
|
CA2697612A1
(en)
*
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Anti-igf-1r antibodies and uses thereof
|
|
WO2011158931A1
(ja)
|
2010-06-17 |
2011-12-22 |
協和発酵キリン株式会社 |
インダゾール誘導体の有用な塩
|
|
CN103108873A
(zh)
|
2010-07-16 |
2013-05-15 |
皮拉马尔企业有限公司 |
作为激酶抑制剂的取代的咪唑并喹啉衍生物
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
US8546443B2
(en)
|
2010-12-21 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Benzylic oxindole pyrimidines
|
|
CN105884900A
(zh)
|
2011-04-19 |
2016-08-24 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
|
WO2012143879A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
|
AR089776A1
(es)
|
2012-01-23 |
2014-09-17 |
Boehringer Ingelheim Int |
5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
WO2016064716A1
(en)
|
2014-10-20 |
2016-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination therapy of tshr antagonist and igfr inhibitor
|
|
EP3294742B1
(en)
|
2015-05-13 |
2020-01-08 |
Boehringer Ingelheim International GmbH |
New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors.
|
|
US11208489B2
(en)
|
2018-01-24 |
2021-12-28 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of thyroid eye disease
|
|
US20210284741A1
(en)
*
|
2018-01-24 |
2021-09-16 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
US10457740B1
(en)
*
|
2018-01-29 |
2019-10-29 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions for treating cancer using P2RX2 inhibitors
|
|
WO2019173352A1
(en)
|
2018-03-05 |
2019-09-12 |
Hznp Limited |
Methods for the treatment of thyroid eye disease
|
|
BR112022003663A2
(pt)
|
2019-08-28 |
2022-05-24 |
Horizon Therapeutics Ireland Dac |
Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
|